Details for Patent: 6,812,233
✉ Email this page to a colleague
Title: | Therapeutic nucleosides |
Abstract: | The use of a 1,3-oxathiolane nucleoside analogue and pharmaceutically acceptable derivatives thereof for the treatment of hepatitis B virus infections is disclosed. Pharmaceutical formulations are also provided. |
Inventor(s): | Liotta; Dennis C. (McDonough, GA) |
Assignee: | Emory University (Atlanta, GA) |
Filing Date: | Jan 15, 1998 |
Application Number: | 09/007,502 |
Claims: | 1. A method of treating an HBV infection in a human having an HBV infection comprising orally administering a pharmaceutical composition suitable for oral administration containing an effective HBV infection treatment amount of a cis isomer of the compound of formula (I) ##STR5## or a pharmaceutically acceptable salt thereof to said HBV infected human. 2. The method of claim 1, in which the compound or salt is administered in a tablet or capsule. 3. A method of treating an HBV infection in a human having an HBV infection comprising injecting said HBV infected human with a sterile liquid pharmaceutical composition containing an effective HBV infection treatment amount of a cis isomer of the compound of formula (I) ##STR6## or a pharmaceutically acceptable salt thereof. 4. A method of treating an HBV infected host which comprises administering an effective HBV treatment amount of the compound ##STR7## or a pharmaceutically acceptable salt thereof to said HBV infected host. 5. A method of treating an HBV infection in a host which comprises administering an effective HBV treatment amount of the compound (.+-.)-cis-1-(2-hydroxymethyl)-1,3-oxathiolan-5-yl)fluorocytosine to said HBV infected host. 6. A method of limiting Hepatitis B virus production in a plurality of human cells containing said virus which comprises the step of applying to said cells containing said virus an amount of the compound cis-1-(2-hydroxymethyl)-1,3-oxathiolan-5-yl)-5-fluorocytosine sufficient to limit production of said virus. 7. A method for the prophylaxis of an HBV infection in a host which comprises administering an effective amount of the compound (.+-.)-cis-1-(2-hydroxymethyl)-1,3-oxathiolan-5-yl)fluorocytosine to said HBV infected host. 8. A method for theMtreatment of a hepatitis B infection in an infected host which comprises administering an effective HBV treatment amount of the compound cis-(2-hydroxymethyl)-1,3-oxathioan-5-yl)-5-fluorocytosine substantially in the form of one optical isomer or its pharmaceutically acceptable salt to the hepatitis B infected host. 9. A method for the treatment of a hepatitis B infection in an infected host which comprises administering an effective HBV treatment amount of a compound consisting essentially of one optical isomer of cis-(2-hydroxymethyl)-1,3-oxathioan-5-yl)-5-fluorocytosine substantially in the form of one optical isomer or its pharmaceutically acceptable salt to the hepatitis B infected host. 10. The method of claim 8, wherein the optical isomer is the (-)-optical isomer. 11. The method of claim 8, wherein the optical isomer is the (+)-optical isomer. 12. The method of claim 9, wherein the optical isomer is the (-)-optical isomer. 13. The method of claim 9, wherein the optical isomer is the (+)-optical isomer. 14. The methods of claims 9-13 wherein the host is a human. |